{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:21:25Z","timestamp":1793506885461,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gusu Health Talent Program Talent Research Project Contract","award":["GSWS2024004"],"award-info":[{"award-number":["GSWS2024004"]}]},{"name":"Project of Medical Research Fund of Jiangsu Provincial Health Commission","award":["H2023020"],"award-info":[{"award-number":["H2023020"]}]},{"name":"Open Research Fund of the National Innovation Center for Advanced Medical Devices","award":["NMED2025CX-01-010"],"award-info":[{"award-number":["NMED2025CX-01-010"]}]},{"name":"Bo Xi Clinical Research Program","award":["BXLC2024013"],"award-info":[{"award-number":["BXLC2024013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01039-3","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:34:55Z","timestamp":1777034095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of targeted chemokine receptor 4 PET\/CT in evaluating active lesions in multiple myeloma, comparison to 18F-FDG PET\/CT"],"prefix":"10.1186","volume":"26","author":[{"given":"Junpeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"12","key":"1039_CR1","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1038\/bcj.2016.118","volume":"6","author":"C Botta","year":"2016","unstructured":"Botta C, Di Martino MT, Ciliberto D, Cuc\u00e8 M, Correale P, Rossi M, et al. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood cancer J. 2016;6(12):e511. https:\/\/doi.org\/10.1038\/bcj.2016.118.","journal-title":"Blood cancer J"},{"key":"1039_CR2","unstructured":"Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W. SEER, cancer statistics review, 1975\u20132010, National Cancer Institute. Bethesda, MD, based on November 2012 SEER data submission, posted to the SEER web site; 2013. http:\/\/seer.cancer.gov\/csr\/1975_2010."},{"issue":"1","key":"1039_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","volume":"12","author":"J Liu","year":"2019","unstructured":"Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J, et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):136. https:\/\/doi.org\/10.1186\/s13045-019-0807-5.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1039_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022;327(5):464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"JAMA"},{"issue":"12","key":"1039_CR5","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1039_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/rlu.0000000000000696","volume":"40","author":"R Fonti","year":"2015","unstructured":"Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, et al. 18F-FDG PET\/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study. Clin Nucl Med. 2015;40(4):303\u20138. https:\/\/doi.org\/10.1097\/rlu.0000000000000696.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"1039_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","volume":"37","author":"YY Lu","year":"2012","unstructured":"Lu YY, Chen JH, Lin WY, Liang JA, Wang HY, Tsai SC, et al. FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37(9):833\u20137. https:\/\/doi.org\/10.1097\/RLU.0b013e31825b2071.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"1039_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46(6):1345\u201350. https:\/\/doi.org\/10.1007\/s00259-019-04312-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1039_CR9","doi-asserted-by":"publisher","first-page":"622501doi","DOI":"10.3389\/fonc.2020.622501","volume":"10","author":"F Matteucci","year":"2020","unstructured":"Matteucci F, Paganelli G, Martinelli G, Cerchione C. PET\/CT in Multiple Myeloma: Beyond FDG. Front Oncol. 2020;10:622501doi. https:\/\/doi.org\/10.3389\/fonc.2020.622501.","journal-title":"Front Oncol"},{"issue":"11","key":"1039_CR10","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1158\/1078-0432.Ccr-09-2329","volume":"16","author":"BA Teicher","year":"2010","unstructured":"Teicher BA, Fricker SP. CXCL12 (SDF-1)\/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927\u201331. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-2329.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1039_CR11","first-page":"200","volume":"91","author":"I Vande Broek","year":"2006","unstructured":"Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica. 2006;91(2):200\u20136.","journal-title":"Haematologica"},{"issue":"5","key":"1039_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00277-010-1098-7","volume":"90","author":"GW Basak","year":"2011","unstructured":"Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A, et al. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol. 2011;90(5):557\u201368. https:\/\/doi.org\/10.1007\/s00277-010-1098-7.","journal-title":"Ann Hematol"},{"issue":"4","key":"1039_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00259-017-3831-0","volume":"45","author":"X Li","year":"2018","unstructured":"Li X, Heber D, Leike T, Beitzke D, Lu X, Zhang X, et al. [68Ga]Pentixafor-PET\/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2018;45(4):558\u201366. https:\/\/doi.org\/10.1007\/s00259-017-3831-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1039_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/rlu.0000000000003750","volume":"47","author":"Z Chen","year":"2022","unstructured":"Chen Z, Xue Q, Huang C, Yao S, Miao W. Burkitt Lymphoma\/Leukemia Presented on 68Ga-Pentixafor and 18F-FDG PET\/CT. Clin Nucl Med. 2022;47(1):98\u2013100. https:\/\/doi.org\/10.1097\/rlu.0000000000003750.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"1039_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/rlu.0000000000002946","volume":"45","author":"J Ding","year":"2020","unstructured":"Ding J, Tong A, Zhang Y, Wen J, Huo L. Intense 68Ga-Pentixafor Activity in Aldosterone-Producing Adrenal Adenomas. Clin Nucl Med. 2020;45(4):336\u20139. https:\/\/doi.org\/10.1097\/rlu.0000000000002946.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1039_CR16","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/rlu.0000000000005426","volume":"50","author":"M Chavoshi","year":"2025","unstructured":"Chavoshi M, Mirshahvalad SA, Kohan A, Ortega C, Metser U, Farag A, et al. CXCR4-Targeted PET Imaging in Hematologic Malignancies: A Systematic Review and Meta-analysis. Clin Nucl Med. 2025;50(1):e7\u201316. https:\/\/doi.org\/10.1097\/rlu.0000000000005426.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"1039_CR17","doi-asserted-by":"publisher","first-page":"e2532708","DOI":"10.2214\/ajr.25.32708","volume":"225","author":"W Wang","year":"2025","unstructured":"Wang W, Huang M, Tian R, Shen G. Head-to-Head Comparison of (68)Ga-PentixaFor PET\/CT and FDG PET\/CT for Detecting Hematologic and Solid Cancers: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2025;225(2):e2532708. https:\/\/doi.org\/10.2214\/ajr.25.32708.","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"1039_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201404698","volume":"7","author":"K Philipp-Abbrederis","year":"2015","unstructured":"Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7(4):477\u201387. https:\/\/doi.org\/10.15252\/emmm.201404698.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"1039_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","volume":"47","author":"Q Pan","year":"2020","unstructured":"Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2020;47(3):537\u201346. https:\/\/doi.org\/10.1007\/s00259-019-04605-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1039_CR20","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1007\/s00259-024-06621-0","volume":"51","author":"Z Chen","year":"2024","unstructured":"Chen Z, Yang A, Chen A, Dong J, Lin J, Huang C, et al. [(68)Ga]Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [(18)F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2024;51(7):1926\u201336. https:\/\/doi.org\/10.1007\/s00259-024-06621-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1136","key":"1039_CR21","doi-asserted-by":"publisher","first-page":"20211272","DOI":"10.1259\/bjr.20211272","volume":"95","author":"AS Shekhawat","year":"2022","unstructured":"Shekhawat AS, Singh B, Malhotra P, Watts A, Basher R, Kaur H, et al. Imaging CXCR4 receptors expression for staging multiple myeloma by using (68)Ga-Pentixafor PET\/CT: comparison with (18)F-FDG PET\/CT. Br J Radiol. 2022;95(1136):20211272. https:\/\/doi.org\/10.1259\/bjr.20211272.","journal-title":"Br J Radiol"},{"issue":"6","key":"1039_CR22","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1097\/rlu.0000000000005731","volume":"50","author":"H Kaur","year":"2025","unstructured":"Kaur H, Kumar S, Watts A, Singh C, Sachdeva MUS, Sreedharanunni S, et al. 68 Ga-Pentixafor PET\/CT-Based Response Evaluation and its Prognostic Value in Multiple Myeloma: Comparison With IMWG and 18 F-FDG-Based Response. Clin Nucl Med. 2025;50(6):e331\u20139. https:\/\/doi.org\/10.1097\/rlu.0000000000005731.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"1039_CR23","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/1541-7786.Mcr-13-0114","volume":"11","author":"EA Sison","year":"2013","unstructured":"Sison EA, McIntyre E, Magoon D, Brown P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res. 2013;11(9):1004\u201316. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-13-0114.","journal-title":"Mol Cancer Res"},{"key":"1039_CR24","doi-asserted-by":"publisher","unstructured":"Wang F, Jiang Y, Wang L, Chen Y, Zhang Y, Ma M. One-chip isolation of drug-resistant acute myeloid leukemia cells with CXCR4-targeted magnetic fluorescent nanoprobes. Nanomaterials (Basel Switzerland). 2022;12(10). https:\/\/doi.org\/10.3390\/nano12101711.","DOI":"10.3390\/nano12101711"},{"key":"1039_CR25","doi-asserted-by":"publisher","first-page":"117534doi","DOI":"10.1016\/j.lfs.2020.117534","volume":"249","author":"K Mortezaee","year":"2020","unstructured":"Mortezaee K. CXCL12\/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis. Life Sci. 2020;249:117534doi. https:\/\/doi.org\/10.1016\/j.lfs.2020.117534.","journal-title":"Life Sci"},{"issue":"7","key":"1039_CR26","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","volume":"109","author":"Y Alsayed","year":"2007","unstructured":"Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708\u201317. https:\/\/doi.org\/10.1182\/blood-2006-07-035857.","journal-title":"Blood"},{"issue":"8","key":"1039_CR27","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1158\/0008-5472.Can-17-2332","volume":"78","author":"Y Jung","year":"2018","unstructured":"Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang J, Kim JK, et al. CXCL12\u03b3 Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res. 2018;78(8):2026\u201339. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-2332.","journal-title":"Cancer Res"},{"issue":"4","key":"1039_CR28","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1097\/rlu.0000000000003979","volume":"47","author":"Q Pan","year":"2022","unstructured":"Pan Q, Luo Y, Cao X, Li J. 68Ga-Pentixafor PET\/CT Improves the Detection of Recurrent Myeloma in the Temporal Bone Masked by the Physiological 18F-FDG Uptake of the Brain and Extraocular Muscles. Clin Nucl Med. 2022;47(4):e348\u201350. https:\/\/doi.org\/10.1097\/rlu.0000000000003979.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1039_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1200\/jco.1998.16.1.173","volume":"16","author":"Y Sugawara","year":"1998","unstructured":"Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin oncology: official J Am Soc Clin Oncol. 1998;16(1):173\u201380. https:\/\/doi.org\/10.1200\/jco.1998.16.1.173.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"6","key":"1039_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/0969-8051(96)00085-6","volume":"23","author":"MV Knopp","year":"1996","unstructured":"Knopp MV, Bischoff H, Rimac A, Oberdorfer F, van Kaick G. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol. 1996;23(6):845\u20139. https:\/\/doi.org\/10.1016\/0969-8051(96)00085-6.","journal-title":"Nucl Med Biol"},{"issue":"7","key":"1039_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/ni813","volume":"3","author":"I Petit","year":"2002","unstructured":"Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3(7):687\u201394. https:\/\/doi.org\/10.1038\/ni813.","journal-title":"Nat Immunol"},{"issue":"3","key":"1039_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.15096","volume":"184","author":"C Lapa","year":"2019","unstructured":"Lapa C, L\u00fcckerath K, Kircher S, H\u00e4nscheid H, Grigoleit GU, Rosenwald A, et al. Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. Br J Haematol. 2019;184(3):440\u20133. https:\/\/doi.org\/10.1111\/bjh.15096.","journal-title":"Br J Haematol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01039-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01039-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01039-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:13:31Z","timestamp":1780967611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01039-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01039-3","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethics Committee of The First Affiliated Hospital of Soochow University (No. 2024.256).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}